Precipio Announces Q2-2021 and year-end Shareholder Update Call
Conference Call to be held on Monday, August 23rd, 2021 at 5:00 PM ESTNEW HAVEN, Conn., Aug. 12, 2021 (GLOBE...
Day: August 13, 2021
William Guyer to join Corcept as Chief Development Officer
MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology
The exclusively licensed platform has potential application for any tumor target Preclinical development to continue at Mayo Clinic Mustang to...
Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed...
Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
Clinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing Trial start-up activities to support...
Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results
AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
Rapid Micro Biosystems to Announce Second Quarter 2021 Financial Results on August 26, 2021
LOWELL, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update
PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD)...
SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural...
EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update
WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company...
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel...
OpGen Reports Second Quarter 2021 Financial Results and Provides Business Update
Total Revenue for Q2 2021 was approximately $0.8 millionCash as of June 30, 2021 was approximately $31.2 million, up significantly...
CooperCompanies to Participate in the Virtual Wells Fargo Healthcare Conference
SAN RAMON, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), will participate in the Virtual Wells Fargo Healthcare...
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
YTX-7739 shown to inhibit its novel target in healthy volunteers at levels consistent with improved motor function in an animal...
Seer Reports Second Quarter 2021 Financial Results
Expanded installed base and booked initial revenue for Proteograph Product SuiteREDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Seer,...
Better Plant Fights Climate Change with the Launch of EcoCart for Carbon Neutral Online Shopping
VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Better Plant Sciences Inc. (CSE:PLNT) (OTCQB:VEGGF) ("Better Plant" or the "Company"),...
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical...
Dermata Therapeutics, Inc. Announces Pricing of Upsized $18.0 Million Initial Public Offering
SAN DIEGO, CA / ACCESSWIRE / August 12, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage...